These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32090499)

  • 21. Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.
    Volonte D; Peoples AJ; Galbiati F
    Mol Biol Cell; 2003 Oct; 14(10):4075-88. PubMed ID: 14517320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A CAV3 microdeletion differentially affects skeletal muscle and myocardium.
    Cagliani R; Bresolin N; Prelle A; Gallanti A; Fortunato F; Sironi M; Ciscato P; Fagiolari G; Bonato S; Galbiati S; Corti S; Lamperti C; Moggio M; Comi GP
    Neurology; 2003 Dec; 61(11):1513-9. PubMed ID: 14663034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myotonia associated with caveolin-3 mutation.
    Milone M; McEvoy KM; Sorenson EJ; Daube JR
    Muscle Nerve; 2012 Jun; 45(6):897-900. PubMed ID: 22581547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition.
    Ohsawa Y; Hagiwara H; Nakatani M; Yasue A; Moriyama K; Murakami T; Tsuchida K; Noji S; Sunada Y
    J Clin Invest; 2006 Nov; 116(11):2924-34. PubMed ID: 17039257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities.
    Galbiati F; Engelman JA; Volonte D; Zhang XL; Minetti C; Li M; Hou H; Kneitz B; Edelmann W; Lisanti MP
    J Biol Chem; 2001 Jun; 276(24):21425-33. PubMed ID: 11259414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition.
    Capanni C; Sabatelli P; Mattioli E; Ognibene A; Columbaro M; Lattanzi G; Merlini L; Minetti C; Maraldi NM; Squarzoni S
    Exp Mol Med; 2003 Dec; 35(6):538-44. PubMed ID: 14749532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Caveolinopathies in Greece.
    Papadopoulos C; Papadimas GK; Kekou K; Spengos K; Svigou M; Kitsiou-Tzeli S; Manta P
    Neurologist; 2015 Jul; 20(1):8-12. PubMed ID: 26185955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sarcolemmal proteins dysferlin and caveolin-3 interact in skeletal muscle.
    Matsuda C; Hayashi YK; Ogawa M; Aoki M; Murayama K; Nishino I; Nonaka I; Arahata K; Brown RH
    Hum Mol Genet; 2001 Aug; 10(17):1761-6. PubMed ID: 11532985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAV3 gene sequence variations: National Genome Database and clinics.
    Stavusis J; Inashkina I; Jankevics E; Radovica I; Micule I; Strautmanis J; Naudina MS; Utkus A; Burnyte B; Lace B
    Acta Neurol Scand; 2015 Sep; 132(3):185-90. PubMed ID: 25630502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies.
    Scalco RS; Gardiner AR; Pitceathly RD; Hilton-Jones D; Schapira AH; Turner C; Parton M; Desikan M; Barresi R; Marsh J; Manzur AY; Childs AM; Feng L; Murphy E; Lamont PJ; Ravenscroft G; Wallefeld W; Davis MR; Laing NG; Holton JL; Fialho D; Bushby K; Hanna MG; Phadke R; Jungbluth H; Houlden H; Quinlivan R
    Neuromuscul Disord; 2016 Aug; 26(8):504-10. PubMed ID: 27312022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex.
    Galbiati F; Volonte D; Minetti C; Chu JB; Lisanti MP
    J Biol Chem; 1999 Sep; 274(36):25632-41. PubMed ID: 10464299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease.
    Betz RC; Schoser BG; Kasper D; Ricker K; Ramírez A; Stein V; Torbergsen T; Lee YA; Nöthen MM; Wienker TF; Malin JP; Propping P; Reis A; Mortier W; Jentsch TJ; Vorgerd M; Kubisch C
    Nat Genet; 2001 Jul; 28(3):218-9. PubMed ID: 11431690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Limb-girdle muscular dystrophy in a 71-year-old woman with an R27Q mutation in the CAV3 gene.
    Figarella-Branger D; Pouget J; Bernard R; Krahn M; Fernandez C; Lévy N; Pellissier JF
    Neurology; 2003 Aug; 61(4):562-4. PubMed ID: 12939441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases.
    Sotgia F; Bonuccelli G; Minetti C; Woodman SE; Capozza F; Kemp RG; Scherer PE; Lisanti MP
    Am J Pathol; 2003 Dec; 163(6):2619-34. PubMed ID: 14633633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia.
    Carbone I; Bruno C; Sotgia F; Bado M; Broda P; Masetti E; Panella A; Zara F; Bricarelli FD; Cordone G; Lisanti MP; Minetti C
    Neurology; 2000 Mar; 54(6):1373-6. PubMed ID: 10746614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease.
    Kubisch C; Schoser BG; von Düring M; Betz RC; Goebel HH; Zahn S; Ehrbrecht A; Aasly J; Schroers A; Popovic N; Lochmüller H; Schröder JM; Brüning T; Malin JP; Fricke B; Meinck HM; Torbergsen T; Engels H; Voss B; Vorgerd M
    Ann Neurol; 2003 Apr; 53(4):512-20. PubMed ID: 12666119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caveolin-3 regulates myostatin signaling. Mini-review.
    Ohsawa Y; Okada T; Kuga A; Hayashi S; Murakami T; Tsuchida K; Noji S; Sunada Y
    Acta Myol; 2008 Jul; 27(1):19-24. PubMed ID: 19108573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy.
    Minetti C; Sotgia F; Bruno C; Scartezzini P; Broda P; Bado M; Masetti E; Mazzocco M; Egeo A; Donati MA; Volonte D; Galbiati F; Cordone G; Bricarelli FD; Lisanti MP; Zara F
    Nat Genet; 1998 Apr; 18(4):365-8. PubMed ID: 9537420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity.
    Ohsawa Y; Toko H; Katsura M; Morimoto K; Yamada H; Ichikawa Y; Murakami T; Ohkuma S; Komuro I; Sunada Y
    Hum Mol Genet; 2004 Jan; 13(2):151-7. PubMed ID: 14645200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable reduction of caveolin-3 in patients with LGMD2B/MM.
    Walter MC; Braun C; Vorgerd M; Poppe M; Thirion C; Schmidt C; Schreiber H; Knirsch UI; Brummer D; Müller-Felber W; Pongratz D; Müller-Höcker J; Huebner A; Lochmüller H
    J Neurol; 2003 Dec; 250(12):1431-8. PubMed ID: 14673575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.